Contemporary Outcomes and Trends for the Transseptal Mitral Valve-in-Valve Procedure Using Balloon Expandable Transcatheter Valves in the United States.
Kashish GoelRaj MakkarAmar KrishnaswamySamir R KapadiaSusheel KodaliAshish ShahColin M BarkerKe XuAbhijeet DhoblePradeep YadavCharanjit S RihalAmr E AbbasMayra E GuerreroBrian K WhisenantPublished in: Circulation (2024)
This multicenter, prospective study reports excellent procedural outcomes, 1-year mortality rates, and a significant improvement in quality of life for patients undergoing transseptal MViV in the contemporary era. Patients in the low-risk and intermediate-risk STS score categories had significantly better outcomes compared with those in the high-risk category. MViV is a reasonable therapy for the majority of patients with degenerated bioprosthetic mitral valves, who are anatomical candidates.
Keyphrases
- mitral valve
- aortic valve
- left atrial
- patients undergoing
- aortic valve replacement
- end stage renal disease
- ejection fraction
- aortic stenosis
- left ventricular
- chronic kidney disease
- peritoneal dialysis
- cardiovascular events
- clinical trial
- type diabetes
- prognostic factors
- emergency department
- coronary artery disease
- transcatheter aortic valve implantation
- transcatheter aortic valve replacement
- risk factors
- patient reported outcomes
- electronic health record
- atrial fibrillation
- glycemic control
- adverse drug